RESEARCHER PROFILE

Ivan Krečak

← Back to Šibenik University of Applied Sciences

I

Šibenik University of Applied Sciences

Myeloproliferative Neoplasms: Diagnosis and TreatmentPlatelet Disorders and TreatmentsChronic Lymphocytic Leukemia ResearchHematological disorders and diagnosticsVenous Thromboembolism Diagnosis and Management

Ivan Krečak works in Myeloproliferative Neoplasms: Diagnosis and Treatment, Platelet Disorders and Treatments, Chronic Lymphocytic Leukemia Research, Hematological disorders and diagnostics, Venous Thromboembolism Diagnosis and Management. Recorded institutional associations include University of Rijeka, Šibenik University of Applied Sciences, Opća bolnica Šibenik.

169Publications
685Citations
15H-index

Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.

Selected research works

Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.

  1. Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism

    2021 · 35 citations
  2. Reduced renal function strongly affects survival and thrombosis in patients with myelofibrosis

    2020 · 34 citations
  3. Identifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project

    2023 · 31 citations
  4. Chronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera

    2020 · 29 citations
  5. Advances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia

    2022 · 24 citations
  6. High red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera

    2019 · 23 citations
  7. Neutrophil‐to‐lymphocyte and platelet‐to‐lymphocyte ratios as prognostic biomarkers in polycythemia vera

    2021 · 21 citations
  8. The impact of statins on the intensity of phlebotomies in polycythemia vera

    2020 · 20 citations
  9. Renal disease associated with chronic myeloproliferative neoplasms

    2022 · 19 citations
  10. Thrombotic risk in secondary polycythemia resembles low-risk polycythemia vera and increases in specific subsets of patients

    2021 · 17 citations
  11. Patients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis

    2022 · 17 citations
  12. Higher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis

    2021 · 16 citations
  13. High platelet-to-lymphocyte ratio may differentiate polycythemia vera from secondary polycythemia

    2022 · 15 citations
  14. Polypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms

    2023 · 15 citations
  15. The triple A model (age, absolute neutrophil count, absolute lymphocyte count‐ AAA ) predicts survival and thrombosis in polycythemia vera

    2024 · 15 citations
  16. Estimating plasma volume using the Strauss‐derived formula may improve prognostication in polycythemia vera

    2021 · 13 citations
  17. No Impact of the Increased Number of Cardiovascular Risk Factors on Thrombosis and Survival in Polycythemia Vera

    2021 · 12 citations
  18. Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis

    2023 · 12 citations
  19. Hyperuricemia might promote thrombosis in essential thrombocythemia and polycythemia vera

    2020 · 11 citations
  20. Low-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera

    2021 · 11 citations
  21. Beneficial effect of ACE inhibitors on kidney function in polycythemia vera

    2021 · 11 citations
  22. C reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis

    2020 · 10 citations
  23. Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives

    2023 · 10 citations
  24. Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis

    2024 · 10 citations
  25. Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms

    2019 · 9 citations

← Return to the university profile